Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 21, 2024 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first...
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024 07:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design...
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 16:05 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing...
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
November 07, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 23, 2023 10:30 ET
|
Bolt Biotherapeutics, Inc.
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional...
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 18, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus...
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 17, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid...
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 16, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 28, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001...